author-photo

Joachim Stangier

Boehringer Ingelheim

63

Papers

10123

Citations

Citation Trend

Filter By

Papers (48) Sort By

Journal Conference Others

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran

2019 Journal of Thrombosis and Haemostasis
Show All
- Source
- Cite
- Save
Citations (2)
Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials

2018 Thrombosis and Haemostasis
Show All
- Source
- Cite
- Save
Citations (10)
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study

2017
Show All
- Source
- Cite
- Save
Citations (10)
Authors’ Reply to Kamel et al.: “Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study”

2017 Clinical Pharmacokinectics
Show All
- Source
- Cite
- Save
Citations (12)
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

2017 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (586)
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies

2017 British Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (8)
Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers

2016 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (34)
EVALUATION OF THE IMMUNOGENICITY OF THE DABIGATRAN REVERSAL AGENT IDARUCIZUMAB: POOLED ANALYSIS OF PHASE I DATA

2016 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (3)
Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers

2016 Thrombosis and Haemostasis
Show All
- Source
- Cite
- Save
Citations (22)
Idarucizumab, a Specific Reversal Agent for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran-Induced Anticoagulation in Japanese Healthy Male Volunteers

2016 Blood
Show All
- Source
- Cite
- Save
Citations (4)